Lonza and NeuroSense Therapeutics Ltd., a company developing treatments for amyotrophic lateral sclerosis (ALS) and other severe neurodegenerative diseases, have entered a collaboration to evaluate biological changes occurring in people with neurodegenerative diseases, including ALS.